The receptor tyrosine kinase AXL (RTK-AXL) has been identified as a mediator for tumor progression and therapy resistance in various cancer types, including squamous cell tumors, small cell lung cancer, and breast cancer [8,9,10,11,12,13]. The gene discussed is AXL; the disease is neoplasm.